Mileutis

Company Overview

Snapshot

Founded in January 2004 by David Javier Iscovich, MBA and Jose Iscovich, MD, MSc, Mileutis operates with 11–50 employees. The company has raised $20 million across two funding rounds from NovaQuest Capital Management LLC and Yotvata Dairy. In May 2024, Mileutis secured an investment from Yotvata Dairy, further solidifying its position in the dairy industry.

Business overview

Mileutis is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel, biologically sourced, and residual-free therapies for both animal and human health. The company's core technology involves peptides and specific protein fragments that modulate immune responses, enabling the management of infectious and chronic diseases without antibiotics. Mileutis primarily serves the dairy industry with its lead products, Imilac and Milac, which aim to replace antibiotics in treating and preventing mastitis in dairy cows, thereby improving animal welfare, increasing milk yield, and addressing the global threat of antimicrobial resistance.

Strategic signal

In May 2024, Mileutis announced an investment and expanded collaboration with Yotvata Dairy. This partnership signifies a major step towards redefining sustainable dairy farming by implementing a management system that reduces antibiotic use and enhances milk quality. The collaboration, which follows successful clinical trials of Imilac, indicates strong market validation and a growth-positive trajectory for Mileutis as it aims to replace antibiotics in the dairy sector and contribute to carbon neutrality goals.

Company Intelligence Q&A

What was the most recent significant investment in Mileutis?

In May 2024, Mileutis received an investment from Yotvata Dairy. This funding is part of an expanded collaboration aimed at improving milk quality and reducing antibiotic use in dairy farming.

When did Mileutis raise its initial disclosed funding?

In October 2020, Mileutis raised $20 million from NovaQuest Capital Management LLC. This investment was intended to support the continued development and commercialization of the company's novel animal health therapies.

What was the outcome of Mileutis' clinical trial for Imilac?

In August 2023, Mileutis successfully completed a clinical trial demonstrating that its product, Imilac, can effectively replace antibiotics in dairy cows during the dry-off period. The trial showed enhanced milk nutritional characteristics, increased milk yield, and improved cow welfare.

What is the primary goal of Mileutis' products like Imilac and Milac?

Mileutis' primary goal with products like Imilac and Milac is to manage, treat, and prevent mastitis in dairy cows, replacing antibiotics. This approach aims to improve cow well-being, increase milk yield, and provide economic value to farmers while combating antimicrobial resistance.

What strategic partnerships has Mileutis formed?

Mileutis has formed partnerships with major dairy providers such as Yotvata Dairy and Tnuva. These collaborations are focused on implementing sustainable dairy farming practices and reducing antibiotic use.